Catalyst Capital Advisors’s Cardlytics CDLX Stock Holding History

Catalyst Capital Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-52	Closed	-$11K	–	462
2018 Q2	$11K	Buy	52 +10	+24%	+$1.85K	﹤0.01%	350
2018 Q1	$6K	Buy	+42	New	+$7.1K	﹤0.01%	376

Other funds holding CDLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SRFM

Shannon River Fund Management New York $524M AUM 90.54% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Catalyst Capital Advisors's CDLX Position: Q3 2018 in Review

Catalyst Capital Advisors sold out of Cardlytics (CDLX) in Q3 2018, closing a stake of 52 shares — an estimated $11K sold.

Catalyst Capital Advisors first reported a position in CDLX in Q1 2018 and held it in 2 quarters. The position peaked at $11K in Q2 2018. 58 funds tracked by Wall St. Rank hold CDLX as of Q3 2018.

Catalyst Capital Advisors reported no remaining Cardlytics position as of Q3 2018 after selling out during the quarter.
Catalyst Capital Advisors sold 52 Cardlytics shares in Q3 2018, an estimated $11K.
Catalyst Capital Advisors first reported a position in Cardlytics in Q1 2018 and held it in 2 quarters.
Catalyst Capital Advisors's Cardlytics position peaked at $11K in Q2 2018.
58 funds tracked by Wall St. Rank held Cardlytics as of Q3 2018.

Based on Catalyst Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.